UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 200

Sortiert nach

Histone acetyltransferase p300/CBP inhibitor C646 blocks the survival and invasion pathways of gastric cancer cell lines

International journal of oncology, 2017-12, Vol.51 (6), p.1860-1868

2017

Link zum Volltext

Verfügbarkeit prüfen

Development of a multi‐recombinase polymerase amplification assay for rapid identification of COVID‐19, influenza A and B

Journal of medical virology, 2023-01, Vol.95 (1), p.e28139-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

RON Receptor Tyrosine Kinase in Tumorigenic Stemness as a Therapeutic Target of Antibody-drug Conjugates for Eradication of Triple-negative Breast Cancer Stem Cells

Current cancer drug targets, 2023-01, Vol.23 (2), p.103

2023

Link zum Volltext

Verfügbarkeit prüfen

Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase

Therapeutic Advances in Medical Oncology, 2021, Vol.13, p.17588359211006957-17588359211006957

2021

Link zum Volltext

Verfügbarkeit prüfen

MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy

Journal of experimental & clinical cancer research, 2020-09, Vol.39 (1), p.1-18, Article 198

2020

Link zum Volltext

Verfügbarkeit prüfen

Involvement of the circular RNA/microRNA/glucose-6-phosphate dehydrogenase axis in the pathological mechanism of hepatocellular carcinoma

Hepatobiliary & pancreatic diseases international, 2021-12, Vol.20 (6), p.530-534

2021

Link zum Volltext

Verfügbarkeit prüfen

Molecular Characteristics, Functions, and Related Pathogenicity of MERS-CoV Proteins

Engineering (Beijing, China), 2019-10, Vol.5 (5), p.940-947

2019

Link zum Volltext

Verfügbarkeit prüfen

Multiple variants of the RON receptor tyrosine kinase: Biochemical properties, tumorigenic activities, and potential drug targets

Cancer letters, 2007-11, Vol.257 (2), p.157-164

2007

Link zum Volltext

Verfügbarkeit prüfen

The viral distribution and pathological characteristics of BALB/c mice infected with highly pathogenic Influenza H7N9 virus

Virology journal, 2021-11, Vol.18 (1), p.237-237, Article 237

2021

Link zum Volltext

Verfügbarkeit prüfen

RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer

Cancer Research and Treatment, 2020, 52(3), , pp.973-986

2020

Link zum Volltext

Verfügbarkeit prüfen

An inhibitor of the acetyltransferases CBP/p300 exerts antineoplastic effects on gastrointestinal stromal tumor cells

Oncology reports, 2016-11, Vol.36 (5), p.2763-2770

2016

Link zum Volltext

Verfügbarkeit prüfen

Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody–drug conjugates as lead drug candidates for clinical trials

Therapeutic Advances in Medical Oncology, 2020, Vol.12, p.1758835920920069-1758835920920069

2020

Link zum Volltext

Verfügbarkeit prüfen

Expression of B7-H4 and hepatitis B virus X in hepatitis B virus-related hepatocellular carcinoma

World journal of gastroenterology : WJG, 2016-05, Vol.22 (18), p.4538-4546

2016

Link zum Volltext

Verfügbarkeit prüfen

Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer

Journal of experimental & clinical cancer research, 2016-04, Vol.35 (70), p.70, Article 70

2016

Link zum Volltext

Verfügbarkeit prüfen

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer

Frontiers in oncology, 2019-12, Vol.9, p.1377-1377

2019

Link zum Volltext

Verfügbarkeit prüfen

Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics

Molecular oncology, 2014-05, Vol.8 (3), p.469-482

2014

Link zum Volltext

Verfügbarkeit prüfen

Progress and challenge in development of biotherapeutics targeting MET receptor for treatment of advanced cancer

Biochimica et biophysica acta. Reviews on cancer, 2020-12, Vol.1874 (2), p.188425, Article 188425

2020

Link zum Volltext

Verfügbarkeit prüfen

Host proteins interact with viral elements and affect the life cycle of highly pathogenic avian influenza A virus H7N9

Heliyon, 2024-04, Vol.10 (7), p.e28218-e28218, Article e28218

2024

Link zum Volltext

Verfügbarkeit prüfen

Duocarmycin-based antibody–drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress

Drug discovery today, 2021-08, Vol.26 (8), p.1857-1874

2021

Link zum Volltext

Verfügbarkeit prüfen

Novel pathogenic characteristics of highly pathogenic avian influenza virus H7N9: viraemia and extrapulmonary infection

Emerging microbes & infections, 2020-01, Vol.9 (1), p.962-975

2020

Link zum Volltext

Verfügbarkeit prüfen

Toll-like receptor 7 and 9 expression in peripheral blood mononuclear cells from patients with chronic hepatitis B and related hepatocellular carcinoma

Acta pharmacologica Sinica, 2008-02, Vol.29 (2), p.239-244

2008

Link zum Volltext

Verfügbarkeit prüfen

Chaperones, Membrane Trafficking and Signal Transduction Proteins Regulate Zaire Ebola Virus trVLPs and Interact With trVLP Elements

Frontiers in microbiology, 2018-11, Vol.9, p.2724-2724

2018

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy

Journal for immunotherapy of cancer, 2019-09, Vol.7 (1), p.250-250, Article 250

2019

Link zum Volltext

Verfügbarkeit prüfen

The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells

Molecular cancer, 2011-07, Vol.10 (1), p.82-82, Article 82

2011

Link zum Volltext

Verfügbarkeit prüfen

RON receptor tyrosine kinase in pancreatic ductal adenocarcinoma: Pathogenic mechanism in malignancy and pharmaceutical target for therapy

Biochimica et biophysica acta. Reviews on cancer, 2020-04, Vol.1873 (2), p.188360-188360, Article 188360

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 200

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(110)
Mit Volltextzugriff
(185)

Publikationsform

Artikel
(197)
Tagungsberichte
(3)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(87)
Humans
(82)
Life Sciences & Biomedicine
(80)
Animals
(48)
Oncology
(35)
Mice
(31)
Female
(26)
Cell Line, Tumor
(23)
Male
(22)
Middle Aged
(17)
Receptor Tyrosine Kinase
(16)
Mice, Inbred Balb C
(14)
Transfection
(14)
Adult
(13)
Receptor Protein-Tyrosine Kinases - Metabolism
(13)
Proteins
(12)
Pharmacology & Pharmacy
(11)
Therapeutic Efficacy
(11)
Blotting, Western
(10)
Cell Line
(10)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Histone acetyltransferase p300/CBP inhibitor C646 blocks the survival and invasion pathways of gastric cancer cell lines

Development of a multi‐recombinase polymerase amplification assay for rapid identification of COVID‐19, influenza A and B

RON Receptor Tyrosine Kinase in Tumorigenic Stemness as a Therapeutic Target of Antibody-drug Conjugates for Eradication of Triple-negative Breast Cancer Stem Cells

Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase

MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy

Involvement of the circular RNA/microRNA/glucose-6-phosphate dehydrogenase axis in the pathological mechanism of hepatocellular carcinoma

Molecular Characteristics, Functions, and Related Pathogenicity of MERS-CoV Proteins

Multiple variants of the RON receptor tyrosine kinase: Biochemical properties, tumorigenic activities, and potential drug targets

The viral distribution and pathological characteristics of BALB/c mice infected with highly pathogenic Influenza H7N9 virus

RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer

An inhibitor of the acetyltransferases CBP/p300 exerts antineoplastic effects on gastrointestinal stromal tumor cells

Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody–drug conjugates as lead drug candidates for clinical trials

Expression of B7-H4 and hepatitis B virus X in hepatitis B virus-related hepatocellular carcinoma

Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer

Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics

Progress and challenge in development of biotherapeutics targeting MET receptor for treatment of advanced cancer

Host proteins interact with viral elements and affect the life cycle of highly pathogenic avian influenza A virus H7N9

Duocarmycin-based antibody–drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress

Novel pathogenic characteristics of highly pathogenic avian influenza virus H7N9: viraemia and extrapulmonary infection

Toll-like receptor 7 and 9 expression in peripheral blood mononuclear cells from patients with chronic hepatitis B and related hepatocellular carcinoma

Chaperones, Membrane Trafficking and Signal Transduction Proteins Regulate Zaire Ebola Virus trVLPs and Interact With trVLP Elements

Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy

The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells

RON receptor tyrosine kinase in pancreatic ductal adenocarcinoma: Pathogenic mechanism in malignancy and pharmaceutical target for therapy

Suchergebnisse filtern